Search for a trial

DW-MRI in mediastinal restaging after concomitant chemoradiotherapy and prognosis of trimodality treatment for stage IIIA/B NSCLC with mediastinal lymph node metastases and without supraclavicular lymph node metastases ; NSCLC Stadium IIIA/B N2/3

This study aims to investigate the feasability to use DW-MRI for mediastinal restaging after concomitant chemoradiotherapy and the feasabilitiy to predict whether or not mediastinal downstaging will be achieved during concomitant chemoradiotherapy…

89Zr-pembrolizumab-PET imaging in patients with locally advanced or metastatic melanoma or non-small cell lung cancer

Primary objective: To evaluate whole body distribution of 89Zr-pembrolizumab in patients with locally advanced or metastatic melanoma or NSCLC. Secondary objectives: i) To evaluate pharmacokinetics of 89Zr-pembrolizumab; ii) To assess the…

Long term effects of definitive chemoradiotherapy on respiratory function tests in patients with locally advanced (non) small cell lung carcinoma

The aim of the study is to evaluate the change of lung function at least one year after definitive chemoradiation (concurrent or sequential) in patients with locally advanced (non) small cell lung carcinoma to assess late radiation injury in our…

The value of echocardiography for prediction of radiation-induced lung injury in non-small cell lung cancer patients treated with chemo radiation: an onco-cardiac prospective cohort study.

Primary hypothesisCardiac function measured by echocardiography is a prognostic factor for developing radiation-induced dyspnea after (chemo) radiotherapy.Primary objectiveAssess the prognostic value of cardiac function, assessed by clinical…

A non-interventional biomarker study in patients with NSCLC of adenocarcinoma tumour histology eligible for treatment with Vargatef according to the approved label

Research question and objectives: To explore whether genetic/genomic markers (alone or combined with clinical covariates) could be used to predict OS in NSCLC patients treated with Vargatef® according to the approved label.

Treating metastatic lung cancer. What are patients* and physicians* goals and are they achieved?

To examine the goals of patients and doctors for treatment with chemotherapy, immunotherapy or targeted therapy in metastatic lung cancer and whether these goals are achieved according to patients, doctors and relatives.

Phase Ib, open-label, multi-center study to characterize the safety, tolerability and pharmacodynamics (PD) of PDR001 in combination with LCL161, everolimus (RAD001) or panobinostat (LBH589) (CPDR001X2102)

Primary: To characterize the safety and tolerability of PDR001 in combination with LCL161, everolimus, HDM201, QBM076 or panobinostat and to identify recommended doses and schedules for future studies.Secondary: To characterize changes in the immune…

ELDAPT: Elderly with locally advanced Lung cancer: Deciding through geriatric Assessment on the oPtimal Treatment strategy

Developing a clinically applicable geriatric screening instrument to stratify medically fit patients who may benefit from intensified treatment strategies and frail patients who will undergo best supportive care (which may include palliative RT), (2…

proSpecTive sAmpling in dRiver muTation pulmonary oncology patients on Tyrosine Kinase Inhibitors

To collect repeated samples of blood from patients (starting) on TKI, for liquid mutation testing to assess the clinical relevant cutoff value, and pharmacokinetic analysis.

Feasibility trial on combination of platinum doublets and hypofractionated radiotherapy for locally advanced stage non-small cell lung carcinoma

To assess the safety of cisplatin doublets with hypofractionated radiotherapy (24 x2.75Gy).